Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), today announced that it received approximately $1.65 million from the exercise of warrants that had an expiration date of March 1, 2013. In connection with the exercise of these warrants, the Company issued...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it passed its annual independent quality audit and, with all external and mechanical testing completed, plans to apply the Edition 3 CE Mark to the LuViva® Advanced Cervical Scan for expanded...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), today announced it has acquired world-wide rights to develop a non-invasive esophageal cancer detection product from Konica Minolta. The product will be based on Guided Therapeutics’ patented biophotonic...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced plans to showcase the LuViva® Advanced Cervical Scan at the 38th Annual Arab Health...
Guided Therapeutics, Inc., (OTCBB: GTHP) (OTCQB: GTHP), developer of the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, today announced that Mark L. Faupel, Ph.D., President and CEO, is scheduled to present...
Guided Therapeutics, Inc., (OTCBB: GTHP) (OTCQB: GTHP), today announced that it has successfully completed third-party testing of the LuViva® Advanced Cervical Scan. This puts LuViva in compliance with Canadian Standards Association (CSA®) requirements which, while...
